Televisione e Infanzia. Rapporto sull’offerta televisiva per bambini in Italia

Il presente report restituisce i risultati della prima annualità (2011-2012) della ricerca denominata “Televisione e Infanzia”, realizzata da OssCom – Centro di ricerca sui media e la comunicazione dell’Università Cattolica del Sacro Cuore per conto della Fondazione per la Sussidiarietà, nel quadro delle attività di Focus in Media, al fine di ricostruire e descrivere l’offerta televisiva specificamente rivolta al pubblico dei bambini e dei preadolescenti

Multimodal imaging for clinical target volume definition in prone whole-breast irradiation: a single institution experience

Aim: The aim was identification of reference structures for breast clinical target volume (CTV) in prone position, throughout image fusion process. Materials & methods: We analyzed breast glandular tissue distribution in 20 diagnostic MRIs, referring to structures reported in ESTRO guidelines for supine irradiation. The volume containing breast glandular tissue in all cases was defined as MRI prone CTV (MRIpCTV). Then in ten subsequent patients planned for prone irradiation, MRI and computed tomography (CT) simulation was acquired. MRIpCTV was defined followed by our findings and transferred to CT for definitive delineation. Results: MRIpCTV was defined by the caudal edge of clavicular head, 3 mm above inframammary fold, by the medial thoracic artery, by a plane passing through the lateral surface of pectoralis muscles, by the anterior surface of pectoralis muscles and 3 mm from the skin. Deformed CTV was consistent with anatomy on CT; the limits chosen for MRIpCTV fit adequately also for CT. Conclusion: Prone irradiation is an alternative set up for selected cases, so the sample is very small. However, our suggestions could be of aid in defining prone CTV. The good consistency between MRI and CT seems to confirm that MRI may be unnecessary in routine practice

Current Role of Minimally Invasive Radical Cholecystectomy for Gallbladder Cancer

Background. For Tis and T1a gallbladder cancer (GbC), laparoscopic cholecystectomy can provide similar survival outcomes compared to open cholecystectomy. However, for patients affected by resectable T1b or more advanced GbC, open approach radical cholecystectomy (RC), consisting in gallbladder liver bed resection or segment 4b-5 bisegmentectomy, with locoregional lymphadenectomy, is considered the gold standard while minimally invasive RC (MiRC) is skeptically considered. Aim. To analyze current literature on perioperative and oncologic outcomes of MiRC for patients affected by GbC. Methods. A Medline review of published articles until June 2016 concerning MiRC for GbC was performed. Results. Data relevant for this review were presented in 13 articles, including 152 patients undergoing an attempt of MiRC for GbC. No randomized clinical trial was found. The approach was laparoscopic in 147 patients and robotic in five. Conversion was required in 15 (10%) patients. Postoperative complications rate was 10% with no mortality. Long-term survival outcomes were reported by 11 studies, two of them showing similar oncologic results when comparing MiRC with matched open RC. Conclusions. Although randomized clinical trials are still lacking and only descriptive studies reporting on limited number of patients are available, current literature seems suggesting that when performed at highly specialized centers, MiRC for GbC is safe and feasible and has oncologic outcomes comparable to open RC

Televisione e infanzia. La parola ai protagonisti

Terzo, e ultimo, rapporto che chiude l’indagine triennale che OssCom, Centro di ricerca sui media e la comunicazione dell’Università Cattolica, ha realizzato con il supporto di Sky Italia per conto di Focus in media – Osservatorio della Fondazione per la Sussidiarietà sul tema della Children’s Television (CT), cioè della televisione rivolta ai bambini e ai preadolescenti nel nostro Paese. Dopo l’analisi dell’offerta di televisione tematica destinata a questo target specifico (primo rapporto) e la descrizione dei discorsi sociali a carattere normativo che esprimono le aspettative nutrite dai diversi attori e stakeholder nei confronti della CT (secondo rapporto), questo report presenta una raccolta ragionata di testimonianze privilegiate maturate nel contesto dell’intero ecosistema della CT. Le domande di ricerca a cui il report risponde è “quali condizioni rendono più facile che la CT risponda efficacemente a tali aspettative” e “perché la CT non è sempre in grado di soddisfarle”. Si è trattato, dunque, di cogliere punti di forza e punti di debolezza della CT in un’ottica sistemica: cercando, cioè, di prendere in considerazione la complessità delle relazioni che legano fra di loro gli attori della filiera produttiva e distributiva, le istituzioni volte alla regolamentazione e al controllo della programmazione, i pubblici diretti e indiretti di questa forma di produzione culturale

Televisione e infanzia. Le aspettative nei confronti dell'offerta televisiva per i bambini

Secondo report dell’indagine triennale che OssCom, Centro di ricerca sui media e la comunicazione dell’Università Cattolica, sta realizzando per Focus in Media, l’osservatorio sulla comunicazione e i media della Fondazione per la Sussidiarietà. In questo report si presenta l’analisi delle aspettative che i diversi soggetti sociali interessati (mercato, istituzioni, società civile, ricercatori) nutrono nei confronti della programmazione della Children’s Television

Poor efficacy of palbociclib in second-line treatment of metastatic lobular breast cancer in a case series: Use before or never more?

n/

A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)

The study was funded and the investigational drug NUC-3373 was supplied by NuCana plc. The centres that conducted this study are National Institute for Health and Care Research (NIHR) Biomedical Research Centres that also receive institutional funding as Cancer Research UK (CRUK) and Experimental Cancer Medicine Centres (ECMC). The Glasgow Experimental Cancer Medicine Centre (ECMC) is funded by Cancer Research UK and The Chief Scientist’s Office, Scotland (grant award A25174).Purpose 5-fluorouracil (5-FU) is inefficiently converted to the active anti-cancer metabolite, fluorodeoxyuridine-monophosphate (FUDR-MP), is associated with dose-limiting toxicities and challenging administration schedules. NUC-3373 is a phosphoramidate nucleotide analog of fluorodeoxyuridine (FUDR) designed to overcome these limitations and replace fluoropyrimidines such as 5-FU. Patients and methods NUC-3373 was administered as monotherapy to patients with advanced solid tumors refractory to standard therapy via intravenous infusion either on Days 1, 8, 15 and 22 (Part 1) or on Days 1 and 15 (Part 2) of 28-day cycles until disease progression or unacceptable toxicity. Primary objectives were maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) and schedule of NUC-3373. Secondary objectives included pharmacokinetics (PK), and anti-tumor activity. Results Fifty-nine patients received weekly NUC-3373 in 9 cohorts in Part 1 (n = 43) and 3 alternate-weekly dosing cohorts in Part 2 (n = 16). They had received a median of 3 prior lines of treatment (range: 0–11) and 74% were exposed to prior fluoropyrimidines. Four experienced dose-limiting toxicities: two Grade (G) 3 transaminitis; one G2 headache; and one G3 transient hypotension. Commonest treatment-related G3 adverse event of raised transaminases occurred in < 10% of patients. NUC-3373 showed a favorable PK profile, with dose-proportionality and a prolonged half-life compared to 5-FU. A best overall response of stable disease was observed, with prolonged progression-free survival. Conclusion NUC-3373 was well-tolerated in a heavily pre-treated solid tumor patient population, including those who had relapsed on prior 5-FU. The MTD and RP2D was defined as 2500 mg/m2 NUC-3373 weekly. NUC-3373 is currently in combination treatment studies. Trial registration Clinicaltrials.gov registry number NCT02723240. Trial registered on 8th December 2015. https://clinicaltrials.gov/study/NCT02723240.Peer reviewe

The pre-launch characterization of SIMBIO-SYS/VIHI imaging spectrometer for the BepiColombo mission to Mercury. I. Linearity, radiometry, and geometry calibrations

Before integration aboard European Space Agency BepiColombo mission to Mercury, the visible and near infrared hyperspectral imager underwent an intensive calibration campaign. We report in Paper I about the radiometric and linearity responses of the instrument including the optical setups used to perform them. Paper II [F. Altieri et al., Rev. Sci. Instrum. 88, 094503 (2017)] will describe complementary spectral response calibration. The responsivity is used to calculate the expected instrumental signal-to-noise ratio for typical observation scenarios of the BepiColombo mission around Mercury. A description is provided of the internal calibration unit that will be used to verify the relative response during the instrument's lifetime. The instrumental spatial response functions as measured along and across the spectrometer's slit direction were determined by means of spatial scans performed with illuminated test slits placed at the focus of a collimator. The dedicated optical setup used for these measurements is described together with the methods used to derive the instrumental spatial responses at different positions within the 3 . 5 ° field of view and at different wavelengths in the 0.4-2.0 μm spectral range. Finally, instrument imaging capabilities and Modulated Transfer Function are tested by using a standard mask as a target

The measurement of the noise-equivalent spectral radiance of SIMBIO-SYS/VIHI spectrometer

We report about the measurement of the Noise- Equivalent Spectral Radiance (NESR) of the VIHI imaging spectromter aboard ESA's Bepi Colombo mission to Mercury. The knowledge of the NESR allows to determine the capability of an optical detector to measure faint signals. A description of the setup used to determine the NESR during the prelaunch calibration campaign is given. The processing of the data col- lected at various operative temperatures and integration times is described. The sensitivity study of the NESR has been performed at the expected detector's temperatures and integration times with the goal to determine the minimum spectral radiance at which VIHI is sensitive during the different observation phases of the mission. A simulation of the expected Signal-to-Noise Ratio (SNR) of VIHI during the different orbital phases is provided

A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)

Purpose: 5-fluorouracil (5-FU) is inefficiently converted to the active anti-cancer metabolite, fluorodeoxyuridine-monophosphate (FUDR-MP), is associated with dose-limiting toxicities and challenging administration schedules. NUC-3373 is a phosphoramidate nucleotide analog of fluorodeoxyuridine (FUDR) designed to overcome these limitations and replace fluoropyrimidines such as 5-FU. Patients and methods: NUC-3373 was administered as monotherapy to patients with advanced solid tumors refractory to standard therapy via intravenous infusion either on Days 1, 8, 15 and 22 (Part 1) or on Days 1 and 15 (Part 2) of 28-day cycles until disease progression or unacceptable toxicity. Primary objectives were maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) and schedule of NUC-3373. Secondary objectives included pharmacokinetics (PK), and anti-tumor activity. Results: Fifty-nine patients received weekly NUC-3373 in 9 cohorts in Part 1 (n = 43) and 3 alternate-weekly dosing cohorts in Part 2 (n = 16). They had received a median of 3 prior lines of treatment (range: 0–11) and 74% were exposed to prior fluoropyrimidines. Four experienced dose-limiting toxicities: two Grade (G) 3 transaminitis; one G2 headache; and one G3 transient hypotension. Commonest treatment-related G3 adverse event of raised transaminases occurred in &lt; 10% of patients. NUC-3373 showed a favorable PK profile, with dose-proportionality and a prolonged half-life compared to 5-FU. A best overall response of stable disease was observed, with prolonged progression-free survival. Conclusion: NUC-3373 was well-tolerated in a heavily pre-treated solid tumor patient population, including those who had relapsed on prior 5-FU. The MTD and RP2D was defined as 2500 mg/m2 NUC-3373 weekly. NUC-3373 is currently in combination treatment studies